Narrative review / 2023
A scoping review found oral curcumin trials suggest clinical benefits in metabolic and musculoskeletal disorders, but show mixed results in other diseases.
A scoping review evaluated 389 citations from human clinical trials investigating the effects of oral curcumin on disease outcomes. Nearly half the citations focused on obesity-associated metabolic disorders (29%) or musculoskeletal disorders (17%), with beneficial effects on clinical outcomes and/or biomarkers reported in 75% of these studies (77% of which were double-blind randomized placebo-controlled trials). Trials on neurocognitive (11%), gastrointestinal (10%), or cancer (9%) categories were fewer and reported mixed results depending on study quality and condition. The authors noted the need for systematic evaluation of diverse formulations and doses in larger trials.
- Study type
- Scoping review of clinical trials
- Who was studied
- 389 human clinical trial citations (selected from 9,528 initial citations)
- What was measured
- Effects of oral curcumin supplementation on human disease outcomes and biomarkers
THE PAPER
Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials.
Panknin TM, Howe CL, Hauer M, Bucchireddigari B, Rossi AM, Funk JL. Int J Mol Sci, 2023.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.